Total Payments
$24,410
2024 Payments
$2,018
Companies
69
Transactions
544
Medicare Patients
3,733
Medicare Billing
$483,608
Payment Breakdown by Category
Research$14,318 (58.7%)
Food & Beverage$9,621 (39.4%)
Education$470.77 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,318 | 3 | 58.7% |
| Food and Beverage | $9,621 | 528 | 39.4% |
| Education | $470.77 | 13 | 1.9% |
Payments by Type
Research
$14,318
3 transactions
General
$10,092
541 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $14,318 | 3 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,231 | 65 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,150 | 68 | $0 (2024) |
| Amgen Inc. | $689.61 | 37 | $0 (2024) |
| Janssen Biotech, Inc. | $514.24 | 26 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $468.79 | 24 | $0 (2024) |
| Celgene Corporation | $439.84 | 29 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $396.98 | 23 | $0 (2024) |
| PFIZER INC. | $389.20 | 22 | $0 (2024) |
| Astellas Pharma US Inc | $335.61 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,018 | 94 | AstraZeneca Pharmaceuticals LP ($239.75) |
| 2023 | $2,354 | 123 | Merck Sharp & Dohme LLC ($203.91) |
| 2022 | $2,215 | 107 | Eli Lilly and Company ($257.00) |
| 2021 | $15,033 | 55 | Eli Lilly and Company ($14,061) |
| 2020 | $341.56 | 17 | SANOFI-AVENTIS U.S. LLC ($99.00) |
| 2019 | $838.16 | 51 | Novartis Pharmaceuticals Corporation ($215.07) |
| 2018 | $1,027 | 59 | Novartis Pharmaceuticals Corporation ($502.36) |
| 2017 | $581.47 | 38 | Novartis Pharmaceuticals Corporation ($171.02) |
All Payment Transactions
544 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: Oncology | ||||||
| 12/16/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $25.35 | General |
| 11/25/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Oncology | ||||||
| 11/05/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $30.23 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.28 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $33.97 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $13.50 | General |
| Category: Hematology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $14.03 | General |
| Category: Hematology/Oncology | ||||||
| 09/19/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: ONCOLOGY | ||||||
| 09/10/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $15.94 | General |
| Category: Oncology | ||||||
| 08/26/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $14,061 | 2 |
| POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | Eli Lilly and Company | $257.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 854 | 1,786 | $473,797 | $102,378 |
| 2022 | 5 | 876 | 2,016 | $547,460 | $121,194 |
| 2021 | 7 | 1,075 | 2,052 | $534,649 | $140,059 |
| 2020 | 6 | 928 | 2,065 | $564,055 | $119,977 |
Total Patients
3,733
Total Services
7,919
Medicare Billing
$483,608
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 386 | 889 | $205,359 | $41,770 | 20.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 188 | 490 | $113,190 | $29,615 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 81 | 170 | $58,140 | $11,731 | 20.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 79 | $27,018 | $7,134 | 26.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 75 | 75 | $39,525 | $6,733 | 17.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 72 | 72 | $24,768 | $4,018 | 16.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $5,797 | $1,377 | 23.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 374 | 915 | $211,365 | $42,936 | 20.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 190 | 554 | $127,974 | $34,073 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 97 | 258 | $88,236 | $18,766 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 58 | 132 | $45,144 | $11,987 | 26.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 94 | 94 | $49,538 | $8,972 | 18.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 52 | 52 | $17,888 | $3,082 | 17.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $7,315 | $1,377 | 18.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 491 | 1,273 | $294,060 | $80,478 | 27.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 119 | 227 | $77,634 | $20,799 | 26.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 164 | 218 | $50,358 | $11,422 | 22.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 73 | 73 | $38,471 | $9,102 | 23.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 86 | 109 | $24,901 | $7,018 | 28.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 54 | 54 | $18,576 | $4,282 | 23.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 23 | 28 | $9,576 | $2,209 | 23.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 17 | 17 | $8,959 | $1,841 | 20.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 19 | 21 | $6,993 | $1,620 | 23.2% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 29 | 32 | $5,120 | $1,287 | 25.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 538 | 1,290 | $297,990 | $61,286 | 20.6% |
About Dr. Mohammad Khan, M.D
Dr. Mohammad Khan, M.D is a Hematology & Oncology healthcare provider based in Lake Charles, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427010685.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohammad Khan, M.D has received a total of $24,410 in payments from pharmaceutical and medical device companies, with $2,018 received in 2024. These payments were reported across 544 transactions from 69 companies. The most common payment nature is "" ($14,318).
As a Medicare-enrolled provider, Khan has provided services to 3,733 Medicare beneficiaries, totaling 7,919 services with total Medicare billing of $483,608. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Lake Charles, LA
- Active Since 04/04/2006
- Last Updated 04/27/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1427010685
Products in Payments
- KEYTRUDA (Biological) $1,071
- JEVTANA (Drug) $330.54
- OPDIVO (Biological) $260.60
- KISQALI (Drug) $225.10
- LUMAKRAS (Drug) $218.46
- Lenvima (Drug) $211.99
- REBLOZYL (Biological) $208.99
- COSENTYX (Biological) $207.00
- GILOTRIF (Drug) $205.05
- VERZENIO (Drug) $182.92
- PROMACTA (Drug) $182.56
- JAKAFI (Drug) $180.07
- IMBRUVICA (Drug) $179.64
- LUPKYNIS (Drug) $151.50
- LYNPARZA (Drug) $147.08
- XTANDI (Drug) $144.00
- Enhertu (Drug) $143.45
- Pomalyst (Drug) $142.87
- BLENREP (Biological) $139.12
- TASIGNA (Drug) $133.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lake Charles
Kamran Shahid, Md, MD
Hematology & Oncology — Payments: $99,943
Hematology & Oncology $99,943
Dr. Michael Bergeron, M.d, M.D
Hematology & Oncology — Payments: $25,357
Hematology & Oncology $25,357
Dr. Michael Broussard, M.d, M.D
Hematology & Oncology — Payments: $18,077
Hematology & Oncology $18,077
Dr. Leroy Fredericks, M.d, M.D
Hematology & Oncology — Payments: $17,864
Hematology & Oncology $17,864
Dr. Henry Goolsby, M.d, M.D
Hematology & Oncology
Hematology & Oncology
James Gaharan, M.d, M.D
Hematology & Oncology
Hematology & Oncology